Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | Director | February 25, 2020 | February 27, 2020 |
| NEW AMERICA HIGH INCOME FUND INCHYB · Entity 11337 | Director | February 27, 2023 | March 01, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date February 25, 2020 · Filed February 27, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,117 |
Reported balance
After 2020-02-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-02-25 · Grant · Acquired 4,107 · Balance 17,117 F1: These deferred stock units vest in full on February 25, 2021. Once vested, the settlement of these deferred stock units shall be deferred until the grantee incurs a "separation of service" as that term is defined in Section 409A of the internal revenue code, at which time the deferred stock units shall be settled in five equal annual installments each occurring within 60 days of the anniversary of such event. |
Filing footnotes · ownership attribution and instrument terms
F1: These deferred stock units vest in full on February 25, 2021. Once vested, the settlement of these deferred stock units shall be deferred until the grantee incurs a "separation of service" as that term is defined in Section 409A of the internal revenue code, at which time the deferred stock units shall be settled in five equal annual installments each occurring within 60 days of the anniversary of such event.
NEW AMERICA HIGH INCOME FUND INC
Report date February 27, 2023 · Filed March 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,111 |
Reported balance
After 2023-02-27 transaction · row 1
1 source rowRow 1 · 2023-02-27 · Purchase · Acquired 2,000 · Balance 9,111 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2023 Filed Mar 1, 2023 14:53 UTC | NEW AMERICA HIGH INCOME FUND INC HYB · Entity 11337 | PurchaseCommon Stock | 2,000 | $6.81 | $13,619.80 |
DisclosureSEC source: 0001255647-23-000001 · primary_doc.xml · nonDerivative · entry 1 Bower Joseph L. · CIK 0001227947 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,111 Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 23:50 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 4,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-001359 · ownership.xml · nonDerivative · entry 1 Bower Joseph L. · CIK 0001227947 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,117 F1 · security: These deferred stock units vest in full on February 25, 2021. Once vested, the settlement of these deferred stock units shall be deferred until the grantee incurs a "separation of service" as that term is defined in Section 409A of the internal revenue code, at which time the deferred stock units shall be settled in five equal annual installments each occurring within 60 days of the anniversary of such event. Read SEC document |
| November 27, 2019 Filed Nov 29, 2019 21:06 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-007869 · ownership.xml · nonDerivative · entry 1 Bower Joseph L. · CIK 0001227947 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,010 F1 · shares: The shares of common stock of Anika Therapeutics, Inc. were given by Dr. Bower as a bona fide gift to the President and Fellows of Harvard College, a 501(c)(3) non-profit organization, for no valuable consideration on November 27, 2019. F1 · price: The shares of common stock of Anika Therapeutics, Inc. were given by Dr. Bower as a bona fide gift to the President and Fellows of Harvard College, a 501(c)(3) non-profit organization, for no valuable consideration on November 27, 2019. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 20:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 1,994 | $55.57 | $110,806.58 |
DisclosureSEC source: 0001171843-19-005617 · ownership.xml · nonDerivative · entry 1 Bower Joseph L. · CIK 0001227947 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,010 F1 · price: Represents the weighted average sales price. The shares were sold on 8/20/19 at prices ranging from $55.50 to $55.66 per share. Full information regarding the number of shares sold at each price shall be provided to the Staff, Issuer or any security holder, upon request. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:31 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 3,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001384 · ownership.xml · nonDerivative · entry 1 BOWER JOSEPH I · CIK 0001227947 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,004 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 26, 2020. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:06 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 1,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-000688 · formfour.xml · nonDerivative · entry 1 BOWER JOSEPH I · CIK 0001227947 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,162 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on January 24, 2019. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 21:07 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 1,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-17-000585 · formfour.xml · nonDerivative · entry 1 BOWER JOSEPH I · CIK 0001227947 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,536 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on January 27, 2018. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 00:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 40 | $43.31 | $1,732.40 |
DisclosureSEC source: 0001171843-16-013102 · f4_bower110916.xml · nonDerivative · entry 4 BOWER JOSEPH I · CIK 0001227947 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,542 F3 · security: Reflects an aggregate of 540 shares of common stock sold to satisfy tax obligations related to the exercise of the above listed SARs award by the Reporting Person on November 9, 2016. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 00:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 500 | $43.40 | $21,700.00 |
DisclosureSEC source: 0001171843-16-013102 · f4_bower110916.xml · nonDerivative · entry 3 BOWER JOSEPH I · CIK 0001227947 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,582 F3 · security: Reflects an aggregate of 540 shares of common stock sold to satisfy tax obligations related to the exercise of the above listed SARs award by the Reporting Person on November 9, 2016. Read SEC document |
| November 07, 2016 Filed Nov 10, 2016 00:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionStock Appreciation Right · Derivative | 1,540 | $0.00 Strike: $12.36 | $0.00 |
DisclosureSEC source: 0001171843-16-013102 · f4_bower110916.xml · derivative · entry 5 BOWER JOSEPH I · CIK 0001227947 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,540 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Exercise of stock appreciation rights ("SARs") granted on December 14, 2006, which vested in full immediately on such date, and expiring on December 14, 2016. F1 · derivative.exercise_date: Exercise of stock appreciation rights ("SARs") granted on December 14, 2006, which vested in full immediately on such date, and expiring on December 14, 2016. F1 · derivative.expiration_date: Exercise of stock appreciation rights ("SARs") granted on December 14, 2006, which vested in full immediately on such date, and expiring on December 14, 2016. Read SEC document |
| November 07, 2016 Filed Nov 10, 2016 00:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 431 | $44.26 | $19,076.06 |
DisclosureSEC source: 0001171843-16-013102 · f4_bower110916.xml · nonDerivative · entry 2 BOWER JOSEPH I · CIK 0001227947 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,082 F2 · security: Reflects 431 shares of common stock utilized to cover the exercise price of the above listed SARs award by the Reporting Person on November 7, 2016. Read SEC document |
| November 07, 2016 Filed Nov 10, 2016 00:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 1,540 | $12.36 | $19,034.40 |
DisclosureSEC source: 0001171843-16-013102 · f4_bower110916.xml · nonDerivative · entry 1 BOWER JOSEPH I · CIK 0001227947 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Exercise of stock appreciation rights ("SARs") granted on December 14, 2006, which vested in full immediately on such date, and expiring on December 14, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.